Dear DWR Reader,
I am a little surprised to be writing you this email so soon after we offered new subscriptions to Biotech Supertrader at the discounted rate.
The simple truth is we thought it would take at least a month to reach our subscriber limits.
But we have so many new subscribers as of this morning when I started writing this email, there are only a handful of slots left.
I have been on the phone all morning with the publisher to see if there was any wiggle room for the number of subscriptions we can offer.
I was told in no uncertain terms that when we get to our cap, the offer will be taken down at midnight of that day. No exceptions or extensions.
If you want an opportunity to cash in on the amazing profits available to subscribers of Biotech Supertrader, you need to click on the link below:
https://new.hyperionfinancial.com/premium/BST-intro/
I understand why our publisher won't extend the offer.
The truth is if too many people start buying the same biotech company stocks, it will drive the price up before all of our subscribers are able to take advantage.
I understand that. So I am letting you know that people are signing up a lot faster than we expected.
I don't want you to miss out on this opportunity.
If you are ready to take control of your life and are ready to lock in some truly amazing profits…
Then click the link below to get started:
https://new.hyperionfinancial.com/premium/BST-intro/
I hope you don't miss out on this opportunity. I am not sure when you will be able to subscribe to this service again at this price.
Good Investing!
John Alexander, Editor
Dynamic Wealth Report
| | | | | | Copyright 2015 Hyperion Financial Group, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the Dynamic Wealth Report website and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of Hyperion Financial Group, LLC.
LEGAL DISCLAIMER: Neither Hyperion Financial Group LLC nor any of it's employees, contractors or officers are registered investment advisors or a Broker/Dealer. As such, Hyperion Financial Group, LLC does not offer or provide personalized investment advice. Although Hyperion Financial Group, LLC employees and contractors may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees or contractors to you should be considered personalized investment advice.
Owners and writers may have positions in the securities that are discussed. However, no associated employees or contractors may intentionally engage in any transaction that directly or indirectly competes with the interests of our subscribers. We accept no compensation from any companies mentioned in our reports.
Past performance is no guarantee of future results. All information is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell any security. All opinions, analyses and information contained herein are based on sources believed to be reliable and written in good faith, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. Investments recommended in this publication should only be made after consulting with your financial advisor. | |
No comments:
Post a Comment
Keep a civil tongue.